DJIA 17,031.14 43.63 0.26%
NASDAQ 4,518.90 -48.70 -1.07%
S&P 500 1,984.13 -1.41 -0.07%
market minute promo

Exelixis (NASDAQ: EXEL)

1.74 -0.13 (-6.95%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

EXEL $1.74 -6.95%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.85
Previous Close $1.87
Daily Range $1.74 - $1.86
52-Week Range $1.74 - $8.41
Market Cap $339.5M
P/E Ratio -1.23
Dividend (Yield) $0.00 (0.0%)
Volume 4,564,221
Average Daily Volume 4,539,078
Current FY EPS -$1.43





Exelixis (EXEL) Description

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. Website:

News & Commentary Rss Feed

Why Exelixis Inc. Stock Crashed By 70% in 2014

Exelixis stock got mauled after its lead drug failed to impress in a key late-stage study. Find out whether there's any hope left for this biotech stock or if it's time for investors to kiss it goodbye.

Stocks Hitting 52-Week Lows

Tokai Pharmaceuticals IPO: Lack Of Product Diversity Should Leave Investors Cautious

Exelixis' (EXEL) CEO Michael Morrissey Presents at Morgan Stanley Healthcare Conference (Transcript)

Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST

Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte

Exelixis Slumps 55% on Disappointing Cabozantinib Results - Analyst Blog

Exelixis (EXEL) Enters Oversold Territory - Tale of the Tape

Update: Exelixis COMET-1 Trial Fails: The Impact To My Bull Thesis

Midday Losers From Tuesday, September 2

See More EXEL News...

EXEL's Top Competitors

EXEL $1.74 (-6.95%)
Current stock: EXEL
TMO $122.34 (-0.76%)
Current stock: TMO
ILMN $168.10 (-2.69%)
Current stock: ILMN
WAT $101.23 (-0.54%)
Current stock: WAT